Watson Pharmaceuticals, Inc. (WPI) announced its subsidiary Watson Laboratories, Inc. has received approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for Sildenafil Tablets, 20 mg, the generic equivalent to Pfizer's Revatio. Watson intends to begin shipping the product in the near future.
Revatio is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and delay clinical worsening. For the 12 months ending September 30, 2012, Revatio tablets had total U.S. sales of approximately $339 million.
For comments and feedback: editorial@rttnews.com